Page 96 of 123: studies 951 to 960 of 1,225, newest first. Back to the esketamine overview
The Brown University Psychopharmacology Update May 1, 2026
Patients with treatment‐resistant depression who received a series of treatments with ketamine or esketamine showed a substantial reduction in emergency department visits related to suicidality over a 6‐month period, a study has found. Study participants had a 56.7% response rate of depression symptoms following the acute phase of treatment.
International Journal of Drug Delivery Technology April 30, 2026 Dr. Dheerendra Kumar, Dr. Praveen Sachan, Dr. Piyush Verma
Aim This study aims to compare two treatment procedures (standard selective serotonin reuptake inhibitors and rapid-acting therapies/specifically ketamine) for patients suffering from treatment-resistant depression along with evaluating the effectiveness of these approaches in alleviating symptoms and improving patient outcomes. Materials and Methods This study examined 80 patients suffering...
Psychiatria Polska April 30, 2026 Bronisław Gębik, Katarzyna Bliźniewska-Kowalska, Piotr Gałecki
Od 2000 roku ketamina i jej enancjomery są badane pod kątem swojego działania przeciwdepresyjnego. W niniejszej pracy zostanie krótko podsumowana droga ketaminy od anestetyku do leku przeciwdepresyjnego. W tekście przedstawione zostaną najważniejsze mechanizmy jej działania a także działania jej metabolitów. Praca ta ma na celu opisać rolę konkretnych grup receptorów w aktywacji istotnych...
Pharmaceuticals April 24, 2026 Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli et al.
Background/Objectives: Major depressive disorder (MDD) remains a leading cause of disability worldwide and exhibits substantial biological heterogeneity that is not adequately captured by current symptom-based diagnostic systems. While the classical monoamine hypothesis has historically guided antidepressant development, it does not fully account for variability in treatment response, delayed...
Здобутки клінічної і експериментальної медицини April 22, 2026 А. Н. Решетилов
РЕЗЮМЕ. Кетамін, відомий понад 60 років як дисоціативний анестетик, демонструє унікальний мультимодальний фармакологічний профіль, що виходить за межі класичного NMDA-антагонізму. Ця комплексна дія стала основою для його клінічної еволюції та «перевідкриття» у нових терапевтичних нішах, зокрема у психіатрії. Мета – систематизувати та проаналізувати наукові дані щодо клінічної еволюції кетаміну:...
Current Pain and Headache Reports April 21, 2026 Navy C Coggins, Hanson A Chokr, Tricia A Meyer et al.
PURPOSE OF REVIEW: Ketamine was originally developed as a dissociative anesthetic and has remained a valuable agent in anesthesia related to its ability to preserve airway reflexes and relative hemodynamic stability. Over time, its clinical applications have expanded beyond procedural sedation to include roles in pain management and psychiatry. In pain medicine, the therapeutic rationale is...
Molecular Psychiatry April 13, 2026 Xin Zhao, Xinyu Zhang, Shiying Yuan et al.
Ketamine, a potent N-methyl-D-aspartate receptor (NMDAR) antagonist, is widely used for anesthesia and analgesia and, because of its rapid antidepressant effects, in psychiatry. Increasing evidence suggests that ketamine and its enantiomers-(R)-ketamine (arketamine) and (S)-ketamine (esketamine)-also modulate systemic immunity and provide organ protection, partly through interactions with the...
Journal of General Internal Medicine April 1, 2026 Katherine Drabiak 2 citations
Clinics across the USA advertise ketamine as an alternative solution for mental health conditions. Ketamine has expanded into a multibillion-dollar industry, with three delivery models: (1) in-person clinics offering off-label racemic ketamine; (2) clinic visits for esketamine (Spravato); and (3) telehealth services prescribing off-label racemic ketamine. About half of the market encompasses...
Scientific Reports March 27, 2026 Gianmauro Palombelli, Valentina Zecca, Marta Boffa et al. 1 citation
Major depressive disorder is highly prevalent and disabling, and many patients do not respond to standard therapies, resulting in treatment-resistant depression (TRD). Progress in TRD requires preclinical models with poor response to conventional treatments. The Wistar-Kyoto rat exposed to chronic mild stress (WKY/CMS) offers a robust paradigm: it shows limited responsiveness to standard...
Expert Opinion on Pharmacotherapy March 24, 2026 Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri et al.
INTRODUCTION: After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior. AREAS COVERED: This narrative review critically examined the current clinical and regulatory...